Patents by Inventor Rupa Shetty

Rupa Shetty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDK Inhibitors And Their Use As Pharmaceuticals
    Publication number: 20230242543
    Abstract: The disclosure is directed to, in part, to CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
    Type: Application
    Filed: April 4, 2023
    Publication date: August 3, 2023
    Inventors: Liang Lu, Rupa Shetty, Andrew Paul Combs, Chaofeng Dai, Raul Andrew Leal, Klare Lazor Bersch
  • CDK inhibitors and their use as pharmaceuticals
    Patent number: 11673893
    Abstract: The disclosure is directed to, in part, to CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: June 13, 2023
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Liang Lu, Rupa Shetty, Andrew Paul Combs, Chaofeng Dai, Raul Andrew Leal, Klare Lazor Bersch
  • CDK Inhibitors And Their Use As Pharmaceuticals
    Publication number: 20230144528
    Abstract: The disclosure is directed to, in part, to CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
    Type: Application
    Filed: September 30, 2022
    Publication date: May 11, 2023
    Inventors: Liang Lu, Rupa Shetty, Andrew Paul Combs, Chaofeng Dai, Raul Andrew Leal, Klare Lazor Bersch
  • BRM Targeting Compounds And Associated Methods Of Use
    Publication number: 20230083376
    Abstract: The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.
    Type: Application
    Filed: November 8, 2021
    Publication date: March 16, 2023
    Inventors: Liang Lu, Andrew Paul Combs, Corey Howard Basch, Rupa Shetty, Chaofeng Dai, Klare Lazor Bersch, John A. Rose, Danielle Julie Beam, Song Mei
  • Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein
    Publication number: 20230010358
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: August 17, 2021
    Publication date: January 12, 2023
    Inventors: Jincong Zhuo, Raul Leal, Rupa Shetty, Juan Luengo, Andrew Paul Combs, Peng Wei
  • CDK Inhibitors And Their Use As Pharmaceuticals
    Publication number: 20220324830
    Abstract: The disclosure is directed to, in part, to CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
    Type: Application
    Filed: September 11, 2020
    Publication date: October 13, 2022
    Inventors: Liang Lu, Rupa Shetty, Andrew Paul Combs, Chaofeng Dai, Raul Andrew Leal, Klare Lazor Bersch
  • Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
    Publication number: 20220218732
    Abstract: The disclosure is directed to methods of treating disease using compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI:
    Type: Application
    Filed: April 3, 2020
    Publication date: July 14, 2022
    Inventors: Juan Luengo, Raul A. Leal, Hong Lin, Rupa Shetty, Krishna Vaddi
  • SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
    Publication number: 20220177481
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: February 17, 2022
    Publication date: June 9, 2022
    Inventors: Juan Luengo, Hong Lin, Michael Hawkins, Rupa Shetty, Philip Pitis, Gisela Saborit Villarroya
  • Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5)
    Publication number: 20220153747
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: November 18, 2021
    Publication date: May 19, 2022
    Inventors: Hong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins
  • Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
    Publication number: 20220152073
    Abstract: The disclosure is directed to methods of treatment using compounds of Formula (I).
    Type: Application
    Filed: April 3, 2020
    Publication date: May 19, 2022
    Inventors: Hong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins, Philip Pitis, Gisela Saborit Villarroya
  • Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
    Publication number: 20220152072
    Abstract: The disclosure is directed to methods of treating disease using compounds of Formula (I).
    Type: Application
    Filed: April 3, 2020
    Publication date: May 19, 2022
    Inventors: Hong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins
  • Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
    Patent number: 11254683
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: February 22, 2022
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Juan Luengo, Hong Lin, Michael Hawkins, Rupa Shetty, Philip Pitis, Gisela Saborit Villarroya
  • Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
    Patent number: 11220524
    Abstract: The disclosure is directed to compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI: Methods of their use in inhibiting a protein arginine methyltransferase 5 (PRMT5) enzyme and treating disease, as well as methods of their preparation are also described.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: January 11, 2022
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Juan Luengo, Raul A. Leal, Hong Lin, Rupa Shetty, Krishna Vaddi
  • Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
    Patent number: 11214574
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: January 4, 2022
    Assignee: Prelude Therapeutics, Incorporated
    Inventors: Juan Luengo, Hong Lin, Michael Hawkins, Rupa Shetty, Philip Pitis, Gisela Saborit Villarroya
  • Selective inhibitors of protein arginine methytransterase 5 (PRMT5)
    Patent number: 11208416
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: December 28, 2021
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Hong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins
  • Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein
    Patent number: 11130769
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: September 28, 2021
    Assignee: Prelude Therapeutics, Incorporated
    Inventors: Jincong Zhuo, Raul Leal, Rupa Shetty, Juan Luengo, Andrew Paul Combs, Peng Wei
  • Selective inhibitors of protein arginine methlytransferase 5 (PRMT5)
    Patent number: 11078205
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: August 3, 2021
    Assignee: Prelude Therapeutics, Incorporated
    Inventors: Hong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins
  • SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
    Publication number: 20210130388
    Abstract: The disclosure is directed to compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI: Methods of their use in inhibiting a protein arginine methyltransferase 5 (PRMT5) enzyme and treating disease, as well as methods of their preparation are also described.
    Type: Application
    Filed: February 20, 2018
    Publication date: May 6, 2021
    Inventors: Juan LUENGO, Raul A. LEAL, Hong LIN, Rupa SHETTY, Krishna VADDI
  • CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20210070761
    Abstract: The disclosure is directed to, in part, to CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
    Type: Application
    Filed: September 11, 2020
    Publication date: March 11, 2021
    Inventors: Liang Lu, Rupa Shetty, Andrew Paul Combs, Chaofeng Dai, Raul Andrew Leal, Klare Lazor Bersch
  • Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5)
    Publication number: 20200361946
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: August 5, 2020
    Publication date: November 19, 2020
    Inventors: Hong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins